Ro Khanna bought Pliant Therapeutics Inc (NASDAQ: PLRX)
Ro Khanna (D-CA), a U.S. Representative, has disclosed 1 trade in Pliant Therapeutics Inc (PLRX) since 2021, a single purchase, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Ro Khanna bought $1,001 - $15,000 of Pliant Therapeutics Inc (NASDAQ: PLRX) on September 7, 2021. Since that trade, PLRX is down -94.47% against the S&P 500 up +75.33%, an outperformance of -169.80%.
Data updated
Ro Khanna's PLRX trades vs the price
PLRX is down -94.47% since Ro Khanna bought on September 7, 2021, versus +75.33% for the S&P 500.
Performance since this trade
All Ro Khanna PLRX trades
Ro Khanna & PLRX trading FAQ
Is it legal for Ro Khanna to trade Pliant Therapeutics Inc (PLRX) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Pliant Therapeutics Inc (PLRX), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Ro Khanna buy PLRX?
Ro Khanna disclosed a purchase of $1,001 - $15,000 of Pliant Therapeutics Inc (PLRX) on September 7, 2021, according to public STOCK Act filings.
How has PLRX performed since Ro Khanna's trade?
Since Ro Khanna bought PLRX on September 7, 2021, the stock is down -94.47%, versus +75.33% for the S&P 500 over the same period, an outperformance of -169.80%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional PLRX trades?
Quantellect tracks every disclosed congressional trade in Pliant Therapeutics Inc (PLRX) on the Pliant Therapeutics Inc congressional trading page, which aggregates filings across all members of Congress.
Ro Khanna's PLRX tradesAll congressional filings for Pliant Therapeutics IncRo Khanna's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.